Advances in aptamer-based nuclear imaging

Song, Wenyu; Song, Yangmeihui; Li, Qian; Fan, Chunhai; Lan, Xiaoli; Jiang, Dawei

doi:10.1007/s00259-022-05782-0

Cited by 26 publications

(10 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…), recently gained significant attention due to their high affinity and specificity when binding with biological molecules. Recently, they have also been employed in radiolabelled imaging techniques such as single photon emission computed tomography (SPECT) and positron emission tomography (PET) [ 32 , 33 ]. From the pool of several techniques for radiolabelled drug delivery, we will be concentrating on peptide-based delivery, which offers several advantages such as an enhanced targeting effect, low systemic toxicity, and easy mass production [ 34 ] ( Scheme 1 ).…”

Section: Introductionmentioning

confidence: 99%

Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics

Chakraborty

Mondal

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Radiopharmaceutical therapy, which can detect and treat tumours simultaneously, was introduced more than 80 years ago, and it has changed medical strategies with respect to cancer. Many radioactive radionuclides have been developed, and functional, molecularly modified radiolabelled peptides have been used to produce biomolecules and therapeutics that are vastly utilised in the field of radio medicine. Since the 1990s, they have smoothly transitioned into clinical application, and as of today, a wide variety of radiolabelled radionuclide derivatives have been examined and evaluated in various studies. Advanced technologies, such as conjugation of functional peptides or incorporation of radionuclides into chelating ligands, have been developed for advanced radiopharmaceutical cancer therapy. New radiolabelled conjugates for targeted radiotherapy have been designed to deliver radiation directly to cancer cells with improved specificity and minimal damage to the surrounding normal tissue. The development of new theragnostic radionuclides, which can be used for both imaging and therapy purposes, allows for more precise targeting and monitoring of the treatment response. The increased use of peptide receptor radionuclide therapy (PRRT) is also important in the targeting of specific receptors which are overexpressed in cancer cells. In this review, we provide insights into the development of radionuclides and functional radiolabelled peptides, give a brief background, and describe their transition into clinical application.

show abstract

Section: Introductionmentioning

confidence: 99%

Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics

Chakraborty

Mondal

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Due to their great target affinity, enhanced heat stability, and excellent biocompatibility, aptamers prove promising for molecular imaging. Last two decades, we have witnessed the development of aptamer-based molecular imaging using various imaging modalities [26], such as fluorescent imaging [27,28], ultrasound molecular imaging [29,30], magnetic resonance imaging [31,32], and nuclear medicine imaging techniques [33][34][35] including positron emission tomography (PET) and single-photon emission computed tomography (SPECT). Nuclear medicine imaging utilizes probes carrying radioactive isotopes for imaging, generally named radiopharmaceuticals or radiotracers.…”

Section: Introductionmentioning

confidence: 99%

Preliminary evaluation of a 64Cu-labeled DNA aptamer for PET imaging of glioblastoma

Wang

et al. 2023

J Radioanal Nucl Chem

View full text Add to dashboard Cite

To develop a DNA aptamer-based PET tracer for imaging of glioblastoma. 5 mM of NOTA-AS1411, 60-min, and 37 °C were selected as the optimal condition for 64Cu radiolabeling of AS1411. 64Cu-NOTA-AS1411 remained stable in PBS and 100% mouse serum for at least six hours. From the PET images, 64Cu-NOTA-AS1411 tended to be excreted out through the kidneys and there was high tracer accumulation in the bladder. There was a higher tumor uptake in the AS1411 group than that in the control group. 64Cu-NOTA-AS1411 is a suitable potential PET tracer for imaging murine glioblastoma.

show abstract

“…3) Aptamer-guided targeting imaging of disease-related biomarkers ( Filippi et al, 2020 ). With the help of aptamers’ superior specific binding capacity, the combination of aptamers with radionuclides successfully realized targeted cancer theranostics ( Song et al, 2022 ). To give a comprehensive landscape of functional oligonucleotides-based molecular imaging, herein, we review recently reported oligonucleotides radiolabeling strategies and highlight respective applications.…”

Section: Introductionmentioning

confidence: 99%

Radiolabeling of functional oligonucleotides for molecular imaging

Liu

Xia

Ding

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Molecular imaging has greatly advanced basic biology and translational medicine through visualization and quantification of molecular events in a cellular context and living organisms. Nuclear medicine, including positron emission tomography (PET) and single-photon emission tomography (SPECT), is one of the most representative molecular imaging modalities which is widely used in clinical theranostics. Recently, numerous molecular imaging agents have been developed to improve the quality and expand the applicable diseases of molecular imaging. Based on the choice of specific imaging agents, molecular imaging is capable of studying tumor biological activities, detecting tumor metastasis, and imaging Alzheimer’s disease-related amyloid proteins. Among these imaging agents, functional oligonucleotides-based imaging probes are becoming increasingly important due to their unique features. Antisense oligonucleotides, small interfering RNA, and aptamers are privileged molecular tools in precision medicine for cancer diagnosis and treatment. These chemically synthesized oligonucleotides without batch-to-batch variations are flexible to incorporate with other molecules without affecting their functionalities. Therefore, through the combination of oligonucleotides with radioisotopes, a series of molecular imaging agents were developed in the past decades to achieve highly sensitive and accurate biomedical imaging modalities for clinical theranostic. Due to the nature of oligonucleotides, the strategies of oligonucleotide radiolabeling are different from conventional small molecular tracers, and the radiolabeling strategy with rational design is highly correlated to the imaging quality. In this review, we summarize recent advancements in functional oligonucleotide radiolabeling strategies and respective molecular imaging applications. Meanwhile, challenges and future development insights of functional oligonucleotide-based radiopharmaceuticals are discussed in the end.

show abstract

Advances in aptamer-based nuclear imaging

Cited by 26 publications

References 104 publications

Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics

Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics

Preliminary evaluation of a 64Cu-labeled DNA aptamer for PET imaging of glioblastoma

Radiolabeling of functional oligonucleotides for molecular imaging

Contact Info

Product

Resources

About